Literature DB >> 24749365

[Value of fGGO in diagnosing stage I lung cancers].

Yan Huang, You-Juan Wang, Wei-Ya Wang, Qiang Pu, Wei-Min Li.   

Abstract

OBJECTIVE: To determine the value of focal area of ground-glass opacity (fGGO) for early detection and diagnosis of lung cancers.
METHODS: We reviewed clinical data of all patients whose chest CT images showed isolated lesions < or = 5 cm in diameter in the Department of Chest Surgery at West China Hospital, Sichuan University between 2007 and 2010. According to the volume of solid components, the lesions were classified as pure ground-glass opacity (pGGO), mixed ground-glass opacity (mGGO) or solid lesions. The malignant ratio and stage of lesions were calculated based on the postoperative pathological tests. The characteristics of CT signs were compared between the benign and malignant lesions.
RESULTS: Of the 202 cases, 63 (included 15 pGGO and 48 mGGO) had fGGO with a malignant ratio of 71.4% (45/63). The percentage of malignant tumors in the mGGO, pGGO and solid lesions was 75.0%, 60.0% and 48.2% respectively. Stage I lung cancers had an occurrence of spiculation, lobulation and vascular convergence in fGGO of over 70%, higher than that of the benign tumors (P < 0.05).
CONCLUSION: fGGO is an important indicator of lung cancer. mGGO is highly likely to be malignant, particularly when one or more signs of spiculation, lobulation and vascular convergence appear.

Entities:  

Mesh:

Year:  2014        PMID: 24749365

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  2 in total

1.  Multi-slice computed tomography characteristics of solitary pulmonary ground-glass nodules: Differences between malignant and benign.

Authors:  Haiyang Hu; Qingguo Wang; Huamei Tang; Liwen Xiong; Qiang Lin
Journal:  Thorac Cancer       Date:  2015-06-12       Impact factor: 3.500

Review 2.  Advances in intelligent diagnosis methods for pulmonary ground-glass opacity nodules.

Authors:  Jing Yang; Hailin Wang; Chen Geng; Yakang Dai; Jiansong Ji
Journal:  Biomed Eng Online       Date:  2018-02-07       Impact factor: 2.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.